BIO.News Newsletter

Congress heads back to work, and we catch up on news including the FDA’s approval of Eli Lilly’s Alzheimer’s drug and what happened at the U.S.-Mexico-Canada Agreement dispute panel on Mexico’s biotech corn ban. (618 words, 3 minutes, 5 seconds)We want your feedback! We are conducting a survey to get reader feedback on the Good Day BIO newsletter and ensure our content best meets your needs. Click here to take our short survey.

Before we head out for the holiday week, we have more on the CDC’s new recommendations for respiratory diseases, a new analysis of the Inflation Reduction Act’s impacts, and a look at two biotech innovators to watch. (659 words, 3 minutes, 17 seconds)We’re taking a publishing break for the July 4 holiday week. We will return on Monday, July 8. In the meantime, keep an eye on Bio.News for breaking news.

Eli Lilly teams up with OpenAI to fight AMR—another way AI could transform biotech. Plus, dengue is surging worldwide, and the CDC says it now threatens the U.S.—but biotech and One Health could help. (512 words, 2 minutes, 33 seconds)

BIO President & CEO John F. Crowley explored the meaning of “innovation, access, and advocacy” at the American Cancer Society Cancer Action Network breakfast yesterday—we have a recap, plus how caregivers are helping researchers find ALS biomarkers. (598 words, 2 minutes, 59 seconds)

A recent WHO report says the pipeline for antibacterials is insufficient to meet the threat of antimicrobial resistance. Meanwhile, the panel deciding whether Mexico’s plan to ban biotech corn violates the U.S.-Mexico-Canada trade agreement is expected to meet this week. (605 words, 3 minutes, 1 second)

The end of last week brought progress on reauthorizing the Pediatric Priority Review Voucher (PPRV) program, and the New York Times turned up the heat on PBMs. (574 words, 2 minutes, 52 seconds)

We launch our new series highlighting companies supported by the NIH SEED program at the NIH Innovation Zone at BIO 2024—today, meet a company using AI to help clinicians assess the effectiveness of neurological and psychiatric therapies. Plus, BIO joins the SAF Coalition and a lot more news. (604 words, 3 minutes, 1 second)

BIO explains why CMS overreach will impede innovation, and we look at how data can improve clinical trial diversity. (532 words, 2 minutes, 39 seconds)

The FDA approved Merck’s vaccine against pneumococcus bacteria, and a former White House official explains why current Medicare policy will harm access to Alzheimer’s treatments. We’re off tomorrow for Juneteenth—which is also World Sickle Cell Day. We explore biotech’s role in reducing inequities that remain. (648 words, 3 minutes, 14 seconds)We're off Wednesday, June 19, for Juneteenth. We'll return to the regular publishing schedule on Thursday, June 20. 

Starting a new week with a look back at what patient advocates said at BIO 2024, and why patient stories matter—plus, rising temperatures nationwide are a reminder of the need to advance biotech solutions. (640 words, 3 minutes, 12 seconds)